Abstract
Clear cell carcinoma of the ovary has shown an exceedingly chemo-resistant phenotype, especially in cases that are recurrent or refractory to previous therapy. Also, progression-free survival was less than 6 months, even in the patients that achieved response when they were treated with conventional anti-cancer cytotoxic agents. We present a case with recurrent and refractory ovarian clear cell carcinoma that achieved complete remission using a combination of bevacizumab, trabectedin and oxaliplatin. The progression-free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2.
© 2012 The Authors. Journal of Obstetrics and Gynaecology Research © 2012 Japan Society of Obstetrics and Gynecology.
MeSH terms
-
Adenocarcinoma, Clear Cell / drug therapy*
-
Adenocarcinoma, Clear Cell / secondary
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Dioxoles / administration & dosage
-
Dioxoles / adverse effects
-
Dioxoles / therapeutic use*
-
Drug Resistance, Multiple
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Lymphatic Metastasis
-
Neoplasm Recurrence, Local
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / adverse effects
-
Organoplatinum Compounds / therapeutic use*
-
Ovarian Neoplasms / drug therapy*
-
Oxaliplatin
-
Remission Induction
-
Tetrahydroisoquinolines / administration & dosage
-
Tetrahydroisoquinolines / adverse effects
-
Tetrahydroisoquinolines / therapeutic use*
-
Trabectedin
Substances
-
Antibodies, Monoclonal, Humanized
-
Dioxoles
-
Organoplatinum Compounds
-
Tetrahydroisoquinolines
-
Oxaliplatin
-
Bevacizumab
-
Trabectedin